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Biochemists aren’t much accustomed to seeing their work in 
the popular press, save for annual coverage of the Nobel prize 
in chemistry. This year, Roderick MacKinnon was recognized for 
working out the atomic structure of an ion channel and Peter 
Agre for discovering that a major protein found in red blood cells 
functions primarily as a water channel. Agre went on to establish 
the family of related channels, which he named “aquaporins.’’ 
Channel  proteins  have  aqueous  pores that cross the cell 
membrane and regulate the 
flow of molecules in and 
out of cells. Water passively 
pours though aquaporins by 
osmosis, moving from low 
to high concentrations 
of solutes. Solving 
the structure of these 
channels provided a 
platform for exploring 
the underlying molecular 
mechanisms that allow 
the proteins to function as 
filters and maintain osmotic 
equilibrium. Robert Stroud 
and colleagues recently solved 
the atomic structure of an 
aquaporin (GlpF) and have 
now solved the structure 
of another water channel 
from Escherichia coli, called 
aquaporin Z, that selectively 
conducts only water at high rates.
Aquaporins form a large, diverse 
family of proteins and have been found in bacteria, plants, and 
animals. There are 11 family members in the human proteome. 
Less than a decade ago, scientists discovered the aquaporin Z 
gene (aqpZ) in E. coli, pointing to the protein’s role in regulating 
water transport in this prokaryote. The high-resolution X-ray 
structures of recombinant aquaglyceroporin glycerol facilitator 
(GlpF)—a channel protein that transports both glycerol and 
water in E. coli—determined by the Stroud group in 2000 and 
of bovine aquaporin 1 (AQP1) from red blood cells, determined 
a year later, revealed how these aquaporins regulate their 
transport and selectivity. The aquaporin Z channel protein in E. 
coli can accommodate a flow of water at rates six times higher 
than GlpF, making it the prime subject for studying the selectivity 
of a high-conducting water channel. And because the two main 
classes of aquaporins occur in E. coli—which means they’re 
exposed to the same cellular environment—and were both 
expressed recombinantly, the opportunities for comparative 
structural and functional analyses, combined with site-directed 
mutagenesis, promise to provide valuable insights into the 
molecular underpinnings of the selectivity of functionally 
different aquaporins.
After fabricating and growing a recombinant form of AqpZ in 
E. coli, David Savage in the Stroud group recovered the proteins 
from the bacterial colonies, then purified and concentrated them. 
The proteins were crystallized—capturing five water molecules 
inside—and then analyzed by state-of-the-art high-resolution 
X-ray diffraction techniques. The architecture of aquaporin Z, the 
researchers report, is typical of aquaporins, with a spiral of eight 
oxygens providing water-binding sites inside the channel and 
amino acid side chains determining the size and 
chemistry of the channel. The outer 
membrane and cytoplasmic 
ends of the channel are 
wider than the interior, 
which is long and narrow. 
This structure confirms 
that aquaporin selectivity 
arises in part from erecting 
a physical barrier: small 
molecules, like water, can 
easily pass, but larger ones 
simply can’t fit. And the 
strategic positioning of 
amino acid residues 
with hydrophilic or 
hydrophobic properties 
along the channel helps 
police the influx of molecules 
based on their affinity for 
water. While it seems two 
amino acid chains located 
in the middle of the channel 
also provide a water-friendly 
surface, Stroud et al. say they play a more intriguing role. Noting 
that the water molecules occupy the channel in single file, 
the scientists explain that such an orientation would normally 
facilitate the random flow of protons (or hydrogen ions), which 
would be lethal to the cell. This central amino acid pair, they say, 
restricts the behavior of water molecules in the center of the 
channel in such a way that prevents “proton jumping’’ yet keeps 
the water flowing.
With two structural models of aquaporins down to the atomic 
level in the same species, scientists can now begin to investigate 
the molecular mechanisms that facilitate their selectivity. The 
importance of understanding these widely distributed channel 
proteins was underscored by the Nobel awards this year. Water 
transport is fundamental to life, and aquaporins are found 
throughout the body. Knowledge of their structure will help 
reveal the molecular mechanics of their specialized feats and 
promise to offer insights into a wide range of human disorders.
Savage DF, Egea PF, Robles Colmenares Y, O’Connell JD III, Stroud 
RM (2003) Architecture and selectivity in aquaporins 2.5 Å x-ray 
structure of aquaporin Z. DOI: 10.1371/journal/pbio.0000072
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Iron is an essential nutrient for sustaining life-forms as diverse as plankton and 
humans. But too much iron, or too little, can spell trouble. Mammalian cells maintain 
the proper balance partly with the help of a specialized cell surface protein called the 
transferrin receptor (TfR). TfRs bind to the iron-carrying transferrin protein (Fe-Tf) and 
escort their cargo to the cell’s interior. (To learn more about iron metabolism, see the 
primer by Tracey A. Rouault in this issue [DOI: 10.3171/journal/pbio.0000079].) This 
receptor also binds the hereditary hemochromatosis protein (HFE), which is mutated in 
individuals who have the common iron-overload disorder hereditary hemochromatosis. 
While the molecular pathway that mediates cellular intake of iron through the TfR is 
known, it was not clear just how TfR assists in iron release to the cell and how it binds 
HFE and transferrin. By introducing 
multiple mutations in human TfRs, 
Pamela Bjorkman and colleagues 
identified functional binding sites 
for transferrin in both its iron-loaded 
and iron-free (apo-Tf) forms and for 
HFE. From these data, the researchers 
mapped out a scenario of the dynamic 
interactions between receptor and 
ligands (the bound molecule) and 
worked out a structure-based model 
for the mechanism of TfR-assisted iron 
release from Fe-Tf.
Bjorkman’s lab, which had previously 
solved the structures of both HFE and 
HFE bound to the TfR, used their structural information to investigate how the proteins 
interact, which amino acid residues are required for binding, whether the two ligands 
bind differently to the receptor, and how HFE binding affects transferrin binding. They 
found that Fe-Tf and HFE occupy the same or an overlapping site on the receptor, 
but since transferrin is much larger than the HFE protein, it appeared that transferrin 
could also interact with other parts of TfR. And it remained to be seen whether TfR 
discriminated between the iron-loaded and iron-free states of transferrin.
In this study, Bjorkman and colleagues expanded their library of TfR mutants to clarify 
the transferrin binding signature on TfR and to see how the TfR mutations affect the 
way apo-Tf and Fe-Tf interact with the receptor. They characterized the binding affinities 
of 30 TfR mutants to HFE and Fe-Tf and to apo-Tf, and they report that mutations in 11 
of the TfR residues interfere with either one or both forms of transferrin. Four of these 
residues are essential for transferrin binding and are conserved in all known TfR DNA 
sequences. Since residues that didn’t have much impact are not conserved, the scientists 
say the results are likely to describe transferrin–TfR interactions for other species as well.
As expected, the most critical residues required for transferrin binding fall within the 
receptor’s helical domain and have significant physical overlap with residues required 
for HFE binding; though some residues that are required for apo-Tf binding do not affect 
Fe-Tf binding. Bjorkman et al. also identify additional residues in another domain on TfR 
(called the protease-like domain) that support Fe-Tf but not apo-Tf binding, confirming 
that the receptor binding footprints of the two metal-binding states of transferrin are 
indeed different. With a structural model showing where Fe-Tf and apo-Tf bind to the 
receptor, they could evaluate how they bind and thus explain how the receptor mediates 
iron release.
By suggesting a mechanism through which TfR binding regulates iron release, this 
structural model of the transferrin–TfR complex will bolster efforts to elucidate the 
molecular details of this process. Confirmation that transferrin and HFE do indeed 
compete for docking privileges reveals a possible role for HFE in maintaining iron 
homeostasis and will provide valuable insights into the dysregulation that leads to 
the warehousing of iron and resulting tissue and organ damage associated with 
hemochromatosis.
Giannetti AM, Snow PM, Zak O, Björkman PJ (2003) Mechanism for multiple ligand 
recognition by the human transferrin receptor. DOI: 10.1371/journal.pbio.0000051
Structural Mechanism Shows How Transferrin Receptor Binds 
Multiple Ligands and Sheds Light on a Hereditary Iron Disease
While osteoporosis is commonly 
thought of as a disease of old women, it’s 
really more a disease of old age. Marked 
by a deterioration of bone density and 
strength, osteoporosis (meaning “porous 
bones’’) often goes undetected until a 
fateful slip results in a serious fracture 
of the hip, spine, or wrist. While it’s true 
that postmenopausal women are much 
more susceptible than men—largely 
owing to their smaller frames—risk for 
men increases exponentially with age. 
Risk factors traditionally reflect lifestyle 
choices, including lack of exercise and 
poor diet, though genetics appears to 
be a major determinant of low bone 
mineral density (BMD), a characteristic 
feature of osteoporosis. Genetic factors 
also influence an individual’s rate of bone 
loss, bone size, and likelihood of falling. 
In a large genetic study of osteoporotic 
Icelanders and their extended families, 
Unnur Styrkársdóttir and colleagues at 
deCODE Genetics in Reykjavik identified 
a candidate gene associated with a 
predisposition for osteoporosis.
Linking specific genes with complex 
diseases like osteoporosis is a tricky 
business. There are likely to be several 
genetic causes, and to find them 
researchers need large populations, 
abundant genetic markers, and 
extensive patient data. In addition to 
powerful genetic resources, researchers 
at deCODE can take advantage of a 
nationwide genealogical database of 
native Icelanders stretching back to 
the country’s origins 1,100 years ago. 
By screening hundreds of affected 
individuals and their families, the 
scientists searched for candidate 
genes underlying osteoporosis and its 
harbinger, low BMD.
While low BMD is the best predictor 
of osteoporotic fracture, peak bone 
mass (mineral mass begins to diminish 
after young adulthood) and the rate of 
postmenopausal bone loss also appear 
to influence risk. Genetics contributes 
to all of these factors. Styrkársdóttir and 
colleagues screened the genealogical 
data on 207 extended families for the 
most clinically relevant phenotypic 
factors—low BMD and osteoporotic 
fractures—to focus their search. 
Screening only affected families with 
these attributes in a genome-wide 
scan, they say, seemed a reasonable 
method for finding susceptibility genes. 
Chromosome Locus 
and Candidate Gene for 
Osteoporosis Identified
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They conducted a series of scans and 
found a significant linkage to the short 
arm of Chromosome 20. This region 
contains six known genes, including 
four genes involved in bone formation 
and osteoblast (bone-forming cell) 
differentiation.
To winnow the list of most likely 
candidate genes, Styrkársdóttir et al. 
screened the genomes of 705 individuals 
with osteoporosis in a case-control study, 
using closely spaced genetic markers 
within the region of interest. This analysis 
pointed to BMP2 as the most likely 
candidate—an enticing finding, because 
BMP2 (bone morphogenetic protein 
2) is known to be involved in bone 
development. Sequencing the BMP2 gene 
in 188 patients and 94 controls to look for 
functional variants that might account 
for a predisposition to osteoporosis 
flagged several possible sequence 
alterations (which were subsequently 
shown to be associated with osteoporosis 
in the larger cohort). Furthermore, an 
independent replication study with 
two groups of postmenopausal Danish 
women—one group with low BMD and 
one with osteoporotic fractures—found 
comparable results, with a higher 
incidence of the BMP2 variants in the 
affected women compared to the 
controls. These variants alone can’t 
explain all of the results, however, 
because a linkage analysis run with 
patients who do not carry these variants 
still shows a likely association in the BMP2 
region, implying that there may be other 
variants in BMP2 or adjacent genes that 
might be influencing osteoporosis.
These results support BMP2 as a likely 
gene for osteoporosis. Future studies 
will determine whether it increases risk 
through its control over peak bone mass, 
as the researchers suggest, or through 
some other mechanism. Styrkársdóttir et 
al. stress that other as-yet-unidentified 
variants within or near BMP2 may also 
account for the linkage they found. 
The researchers hope their work will 
inspire others to replicate their results, 
to confirm and elucidate the role of this 
gene in osteoporosis. Understanding the 
mechanisms and signaling pathways of 
BMP2’s effects could not only identify 
drug targets for osteoporosis therapies, 
but also catch those at high risk before 
they take that fateful fall.
Styrkársdóttir U, Cazier J-B, Kong A, 
Rolfsson O, Larsen H (2003). Linkage of 
osteoporosis to chromosome 20p12 and 
association to BMP2. DOI: 10.1371/journal/
pbio.0000069
Like many complex physiological conditions, obesity results from the interaction 
of multiple genes and environmental factors. Obesity often runs in families, but since 
families tend to share lifestyle habits as well as genes, teasing out genetic factors has 
proved difficult. The search for candidate genes for susceptibility has been further 
complicated by the likelihood that each gene contributes a small effect and that these 
genes may differ in different populations. In a large case-control study of nuclear families 
in France, Philippe Froguel and colleagues used genome-wide scans of a chromosomal 
region linked with susceptibility to identify a new candidate gene for obesity.
The genetic variation that accounts for the near boundless diversity in human form 
and behavior arises from an average 0.1% difference in genome sequence among 
individuals. Much of this variation is due to single nucleotide polymorphisms, or 
SNPs, which occur on average at one locus per 1,000 DNA basepairs, out of a total 3 
billion. Many of these variants occur 
outside of genes, but those found in or 
around genes affect everything from 
individual appearance to susceptibility 
(or resistance) to disease. Specific gene 
variants, called alleles, are linked to 
increased risk for a number of diseases, 
including “monogenic’’ obesity, a rare 
condition in which single genes can 
cause obesity. But most cases of obesity 
are “polygenic,’’ influenced by many 
genes.
Froguel and colleagues had previously 
found a strong linkage between a region 
of chromosome 10 and obesity, with SNPs 
in the GAD2 gene turning up most frequently. GAD2 codes for an enzyme (glutamic 
acid decarboxylase, or GAD65) that catalyzes the production of a neurotransmitter 
(gamma-aminobutyric acid, or GABA) that interacts with a neuropeptide (NPY) in the 
hypothalamus to help stimulate appetite. In an average-weight individual, the metabolic 
effects of orexigenic neuropeptides (which stimulate the appetite, decrease energy use, 
and support fat storage) and those of anorexigenic neuropeptides (which suppress 
appetite, increase energy use, and help burn fat) are kept in balance. It has long been 
thought that alleles affecting metabolism may increase susceptibility by inhibiting 
anorexignic neuropeptides.
Screening genomic data on 575 obese subjects and 646 controls for GAD2 alleles, 
Froguel et al. identified one group of alleles as “protective’’ against obesity and another 
as increasing risk. These links were supported by genetic screens of the nuclear families 
participating in the study, which showed a higher frequency of the protective group 
of alleles in the controls. Obese individuals with two copies of one at-risk allele also 
had more difficulty controlling food intake compared to control subjects, based on a 
standardized assessment of eating behavior. When the researchers investigated the 
physiological effect of the “highest risk’’ GAD2 variant in a mouse cell line, they found 
it caused a 6-fold increase in transcriptional activity compared to the “wild-type’’ cells 
without the variant.
The researchers hypothesize that an overexpression of the GAD2 gene may increase 
the amount of the neurotransmitter GABA in the hyopothalamus, thereby increasing 
GABA’s orexigenic effects and leading to overeating. Studies in turkeys injected with 
muscimol, a GABA activator, and mice overexpressing a protein that regulates GABA 
localization support this notion; the more musimol the turkeys received, the more they 
ate, while the mice gained more weight and showed higher fat deposits.
Genetic factors can’t explain the rapid rise in obesity rates, but they can provide clues 
to preventive and therapeutic approaches to ease the health burden associated with the 
condition. The results to date suggest that GAD2 is a promising candidate gene. Future 
work on the genetics and biology of GAD2 will resolve whether and how the gene 
influences body weight.
Boutin P, Dina C, Vasseur F, Dubois S, Corset L, et al. (2003) GAD2 on chromosome 10p12 is 
a candidate gene for human obesity. DOI: 10.1371/journal.pbio.0000068
GAD2 Identified as Candidate Gene for Obesity
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From the moment a fertilized egg 
starts dividing, its cellular progeny fall 
into a highly coordinated regimen of 
motion, growth, and change. As one cell 
quickly becomes hundreds, some cells 
passively ride the waves of dividing cells, 
while others must navigate uncharted 
territory to reach their destination. Such is 
the fate of germ cells, the guardians 
of genetic inheritance. In the fruitfly 
Drosophila, primordial germ cells 
are among the first cells to develop, 
appearing in the posterior embryo. 
Yet the cells that form the somatic 
tissue of the gonad—where germ 
cells mature into sperm and eggs—
arise in the middle layer of cells, 
called the mesoderm. Primordial 
germ cells must make their way 
through the densely packed cells 
that form the posterior midgut 
epithelium and then negotiate a 
series of topographical landmarks 
before arriving at the gonadal 
mesoderm cells.
The genes and molecules guiding 
germ cells’ improbable migration through 
the posterior midgut are not well known. 
Scientists have only recently discovered 
that a chemokine receptor called 
CXCR4—a member of the G protein-
coupled receptors (GPCRs), the largest 
family of cell-surface receptors—controls 
the migratory pattern of a variety of cell 
types, including leukocytes, neurons, 
and cancer cells. Subsequent studies 
in zebrafish and mice showed that this 
receptor and its ligand (bound molecule) 
guide germ cell migration in vertebrates. 
Now Ruth Lehmann and colleagues have 
identified a novel type of GPCR gene 
called tre1 that is required for the earliest 
stage of active germ cell migration—
passage through the posterior midgut 
epithelium.
Until now, no mutations had been 
identified that affected transepithelial 
migration without disrupting the midgut 
itself. To identify likely candidates, 
Lehmann et al. introduced a series of 
mutations in Drosophila, ranging from 
overexpression to no expression, and 
stained the germ cells to observe the 
mutations’ effects on germ cell migration. 
A laborious series of experiments led 
the authors to a gene that had a very 
interesting germ-cell phenotype (the 
physical effect of the mutation) when 
misexpressed in these cells. After closer 
analysis, they discovered that the gene 
was not normally expressed in germ 
cells and that loss of gene function had 
no effect on these cells. But the authors 
realized they were on the right track since 
the protein sequence of the gene was a 
GPCR and another closely related gene 
produced a striking germ-cell phenotype: 
in some cases, a gonad wound up with 
only one out of the typical 12–15 germ 
cells, while the other cells remained 
trapped in the gut.
This gene, called tre1, had previously 
been considered a taste receptor 
gene until the true taste receptor was 
discovered. Expression pattern studies 
of tre1 showed that it is expressed in 
germ cells and that germ cells lacking 
the Tre1 GPCR display a significant 
defect in migration. Maternal genes 
(gene products from the mother that 
wind up in the embryo) regulate the 
earliest stages of development, and the 
researchers conclude that normal germ-
cell migration through the posterior 
midgut—the first active migratory 
step—depends on maternal tre1 RNA 
and protein deposited in the germ cells. 
And tre1 may be needed only for this 
early step, since the few tre1-mutant cells 
that do pass through the epithelium still 
make it to the gonads. Given the fact that 
tre-1 already had a name, Lehmann et 
al. decided to keep its abbreviation but, 
following genetics tradition, change its 
meaning to describe the phenotype of its 
mutation: trapped in endoderm. While it 
is unclear what ligand activates the Tre1 
receptor, the scientists identified 
a likely downstream target of 
the receptor, called Rho1. When 
this well-known GPCR signaling 
component is disrupted, germ cells 
cannot pass through the posterior 
midgut epithelium.
Tre1, which belongs to a new 
subclass of GPCRs, has three 
Drosophila homologs that are 
expressed in various types of 
migrating cells. Because GPCRs are 
evolutionarily ancient proteins, 
Tre1 and its homologs may have 
conserved functions in directional 
cell migration. Lehmann et al. 
propose that Tre1 functions 
similarly to related chemokine 
receptors active during transepithelial 
migration during an immune 
response—a process that is not well 
understood—and that this new group 
of GPCRs could well control this process, 
as well as a variety of other migratory 
functions. If it turns out that these same 
molecules are also active in cancer—in 
which invasive migratory behavior leads 
to tumor cell metastasis—scientists will 
have a promising lead on finding ways to 
block their action in targeted therapies. 
Lehmann et al. hope these results will 
lay the foundation for such efforts 
by shedding light on the molecular 
mechanisms that drive cell migration 
through tissue.
Kunwar PS, Starz-Gaiano M, Bainton RJ, 
Heberlein U, Lehmann R (2003). Tre1, 
a G protein-coupled receptor, directs 
transepithelial migration of Drosophila germ 
cells. DOI: 10.1371/journal/pbio.0000080
Novel Receptor Guides Germ Cell Transepithelial Migration in Drosophila
Dose of PTEN Gene Drives Progression of Prostate Cancer
Drosophila germ cells migrating through the gut epithelium 
Each year some 29,000 American men die of prostate cancer. With about 221,000 
more diagnoses expected in the United States in 2003, the disease trails only skin 
cancer as the most common male cancer. As a complex disease, multiple genetic and 
environmental factors contribute to risk and, like most cancers, its onset and progression 
depends on the combination of a series of genetic disruptions rather than on a single 
event. But as Pier Paolo Pandolfi and colleagues report, protein “dose’’—that is, the level 
of remaining activity—also influences cancer progression.Volume 1  |  Issue 3  |  Page 306 PLoS Biology  |  http://biology.plosjournals.org
Focusing on the tumor suppressor gene PTEN, the researchers used the mouse as a 
model system to study tumor progression in prostate cancer. PTEN is among the most 
commonly mutated tumor suppressor genes in human cancer. And like many other 
tumor suppressors, PTEN targets proteins in signaling pathways that regulate cell growth 
and apoptosis in healthy tissue and contributes to cancer when dysfunctional. Humans, 
as diploid organisms, generally have two versions of most genes, including PTEN. In the 
event that one copy is damaged or lost, gene function is usually maintained by the other 
copy. In the classic definition of a tumor suppressor, both copies must be lost for a tumor 
to occur. Yet in many cases of advanced cancer, including prostate cancer, only one copy 
is lost at the time a patient shows symptoms. It is then not unreasonable to hypothesize 
that the degree of remaining PTEN activity controls the course of the disease: loss of one 
copy could influence tumor initiation, while further slight reductions might be sufficient 
to facilitate the invasion and metastatic behavior of late-stage cancers.
Pandolfi and colleagues chose two strategies to investigate this hypothesis. In the first 
approach, they genetically engineered one series of mice with minimal levels of murine 
Pten protein (complete loss results in embryo death). This novel “hypomorphic’’ strain of 
mice exhibits only 25%–35% active Pten, which appears to be the minimum level of Pten 
needed to survive embryonic development. This hypomorphic model adds to existing 
strains of fully functional and 50% active Pten mice. In order to model the full loss of 
Pten protein, the researchers generated another series of mice in which Pten genes were 
selectively disabled in the prostate only. The researchers found that subtle reductions 
in Pten dose did indeed produce progressive changes in the biology of the tumor, while 
mice having no functional Pten genes showed the most invasive and aggressive cancers. 
These results, the researchers say, show that Pten plays a “crucial dose-dependent role 
in prostate cancer tumor suppression’’ and that progressive reduction of gene function 
induces progressive changes in the quantity and quality of molecular and pathological 
effects on the pathway to full-blown cancer.
By coupling the molecular genetics and dose of Pten protein with the physiological 
progression of cancer in the prostate, these new mouse models may not only shed 
light on cancer progression in humans, but also help bolster diagnostic, prognostic, 
and therapeutic techniques. While evaluation of tumor status has traditionally been 
determined by pathological analysis of tissue samples, these new models allow 
scientists to pair anatomical stages with underlying molecular events—such as the 
expression level of a single gene or protein—to allow more accurate assessments. These 
molecular profiles can also help researchers design targeted, more efficient prostate 
cancer treatments. For example, if prostate tissue is hypersensitive to reduction of PTEN 
in humans—which the results suggest may be the case, since male mice with only 30% 
of normal Pten levels show massive and selective enlargement of the prostate, and even 
invasive tumors—then ongoing monitoring of PTEN levels could help tailor therapies 
based on promoting PTEN expression. For patients with complete loss of PTEN function, 
where this would not be an option, inhibiting the proteins made overactive through 
PTEN loss could prove effective. And these approaches could well hold true for other 
cancers involving PTEN mutations, including endometrial, brain, and breast cancer.
Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, et al. (2003) Pten dose dictates 
cancer progression in the prostate. DOI: 10.1371/journal.pbio.0000059
Hyperplasia in Pten hypomorphic mice
New Screen Identifies Elusive 
MicroRNA Targets
Biology has come a long way since 
the days of DNA makes RNA makes 
protein. This “central dogma of molecular 
biology’’ does not tell the whole story, 
but then it was not meant to. Francis 
Crick proposed the term in 1958 to 
describe the unidirectional transfer of 
information from a genetic alphabet to 
an amino acid alphabet and saw it as a 
useful model for guiding investigations 
of protein synthesis, at a time when little 
was known about molecular biology. 
Twelve years later, the discovery of 
reverse transcription—the transfer of 
genetic information from RNA to DNA, 
which is how retroviruses invade their 
hosts—was an unexpected change in 
the paradigm. But today the study of 
RNA is a burgeoning field, growing along 
with new discoveries of the molecule’s 
diversity of form and function.
Among the most recently recognized 
RNAs are the “small RNAs.’’ They do not 
code for proteins, but regulate how and 
whether coding RNA, called messenger 
RNA (mRNA), functions. Unknown before 
1993, the 21- to 23-nucleotide transcripts 
known as microRNAs (miRNAs) are 
thought to regulate gene expression by 
binding to mRNAs and inducing their 
cleavage or blocking their translation 
into proteins. Hundreds of miRNAs have 
been identified in plants, worms, flies, 
and humans, but function has been 
attributed to only four animal miRNAs. 
Now Alexander Stark, Julius Brennecke, 
Robert Russell, and Stephen Cohen have 
developed a computational model to 
predict miRNA targets in Drosophila, the 
first step in understanding the functions 
of miRNAs.
Progress in identifying the targets and 
associated functions of animal miRNAs 
has been slow, partly because traditional 
genetics methods—which investigate 
gene function by inducing mutations and 
observing what happens when a gene 
is disabled—are less efficient since the 
genes that code for miRNAs are small. The 
small size of the miRNA sequence also 
hampers computer-based predictions 
of targets. Further complicating matters, 
miRNA/mRNA pairings in animals tend 
to be “imperfect’’—the miRNA sequence 
and the mRNA sequence are not entirely 
complementary—making them harder 
to detect.Volume 1  |  Issue 3  |  Page 307 PLoS Biology  |  http://biology.plosjournals.org
Stark, Brennecke, et al. have overcome 
these problems by combining a 
computational genome screen 
customized to identify potential 
miRNA targets with an RNA-folding 
program that evaluates the structural 
and thermodynamic plausibility of the 
predicted pairs and distinguishes real 
from random matches. The functional 
sites for the few validated miRNA/mRNA 
pairs are all located in the 3' untranslated 
region (UTR) of mRNA and are conserved 
in the same region of homologous genes 
from related species. (Many regulatory 
elements are thought to reside in 
noncoding regions of the genome. 
Two such elements, the 3' UTR and 5' 
UTR of mRNAs, are known to harbor 
sequences essential for gene expression 
and regulation.) To create a database of 
such conserved UTRs, Stark, Brennecke 
et al. compared the UTRs of functionally 
equivalent genes in the fruitfly species 
Drosophila melanogaster and Drosophila 
pseudoobscura. Then they searched 
these conserved genetic elements for 
potential target sequences by requiring 
partial complementarity to the known 
miRNAs. Going a step further, the 
researchers also searched the genome 
of the mosquito Anopheles gambiae—
which diverged from Drosophila some 
250 million years ago—to see whether 
the predicted targets were conserved 
there as well. They found that requiring 
conservation in Anopheles was more 
useful in confirming predicted Drosophila 
targets rather than identifying them.
Efforts to find more animal miRNA 
targets should get easier, the researchers 
suggest, as more is learned about the 
fly and mosquito genomes and as more 
is understood about the structural and 
biochemical nature of miRNA/mRNA 
pairing—for example, which regions and 
structures are essential for pairings. Until 
then, the targets predicted in this new 
screen will help scientists validate more 
miRNA targets and ultimately reveal just 
how large a role these small RNAs play in 
regulating the genome.
Stark A, Brennecke J, Russell RB, Cohen 
SM (2003) Identification of Drosophila 
microRNA targets. DOI: 10.1371/
journal.pbio.0000060
Presence of microRNA (red) inhibits 
expression of the target (green)
While the controversy surrounding the ethics of stem cell 
research shows no signs of abating, scientists continue to 
demonstrate the promise of stem cell–derived therapies for a 
wide range of degenerative diseases. The hope is that stem cells, 
which retain a unique “pluripotent’’ ability to morph into any of 
the 200 cell types of the human body, 
could be used to repair or replace 
damaged or diseased tissue. Many 
animal studies have supported this 
potential for both embryonic and 
adult stem cells, with some findings 
indicating that hematopoietic (blood-
forming) stem cells could be cultured 
and used to help cancer patients who 
need bone-marrow transplants, and 
others suggesting that adult brain 
stem cells could repair damaged nerve 
tissue and help paralysis patients 
recover movement.
Despite these advances, little is 
known about the molecular events that trigger differentiation 
and determine a cell’s developmental potential. Such information 
will help scientists better manipulate this potential in stem-cell 
therapies. Having compiled a comprehensive database of genes 
expressed in mouse early embryos and stem cells, Minoru Ko 
and colleagues present a model that takes the first step toward 
characterizing the molecular profile of stem cells.
Arguing that a broad understanding of these molecular 
determinants requires a broad selection of cell types, the 
scientists combined new gene expression data on early embryos 
and stem cells with existing gene expression data to compare 
transcription patterns across a wide range of cell types and 
developmental stages. The expanded mouse transcriptome 
(record of transcribed genes) included data on unfertilized eggs; 
“totipotent’’ fertilized eggs, which have the potential to become 
any cell; pluripotent embryonic cells; various embryonic and 
adult stem cells; and fully differentiated cells.
Ko et al. characterized gene activity in this diverse cross-
section of cells and looked for molecular differences, including 
the level and type of gene expression, as a measure of 
developmental potential. Applying standard statistical tools 
to spot major trends and clusters in gene expression, the 
researchers found 1,000 new gene 
candidates, which they grouped 
according to particular embryonic 
stage and stem cell type. From these 
signature gene sets, they identified 
a cluster of 88 genes whose average 
expression level decreased as cells 
became more specialized. This finding 
indicates not only that totipotent 
and pluripotent cells have distinct 
genetic profiles, but that these 88 
genes may serve as molecular markers 
of developmental potential. Further 
support of this predictive power 
comes from the finding that adult stem 
cells—cells derived from adult organs that retain a measure of 
pluripotency—were clustered with early embryonic tissues of 
similar potential.
These results are consistent with previous findings that cells 
gradually lose developmental potential and that adult stem 
cells retain plasticity, but more importantly they link signature 
genes with different stem cell types and stages—thus providing 
a preliminary set of molecular markers for characterizing the 
function and potential of different stem cells. Identifying the 
genes that shape the unique properties of stem cells will shed 
light on the molecular pathways that guide development and 
suggest ways to best exploit the full therapeutic potential of 
these embattled cells.
Sharov AA, Piao Y, Matoba R, Dudekula DB, Qian Y, et al. (2003) 
Transcriptome analysis of mouse stem cells and early embryos. DOI: 
10.1371/journal/pbio.0000074
Gene Expression Profile Created for Mouse Stem Cells and Developing Embryo
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When Barbara McClintock discovered 
transposable genetic elements in maize 
in the early 1950s at Cold Spring Harbor 
Laboratory (CSHL) in New York, she 
dubbed them “controlling elements,’’ 
since their manner of jumping from one 
chromosomal site to another controlled 
their own function as well as that of 
nearby genes. Just as genetic material is 
transferred from “parent’’ to “daughter’’ 
cell, these changes in “transposon’’ 
activity, and corresponding 
changes in gene function, are 
inherited by cellular progeny. 
The significance of McClintock’s 
jumping genes was not 
widely recognized at first, but 
transposable elements are now 
considered a classical model 
for epigenetic inheritance—the 
study of heritable changes in 
gene expression and regulation 
that arise independently of 
changes in DNA sequence.
Transposons are normally 
“silent’’—that is, inactive 
and stationary—but various 
mechanisms can rouse them 
and thus influence their 
regulation of gene expression. 
They can be inherited in 
this active state. Because hyperactive 
transposons would cause genetic 
chaos—cancer and other diseases arise 
from misplaced genes—epigenetic 
controls are crucial. A process called 
DNA methylation is thought to keep 
transposons from running amok, but 
other mechanisms that affect epigenetic 
inheritance may also play a role. While 
the molecular basis of these regulatory 
pathways is not clear, it is apparent that 
they interact. Investigating the nature 
and consequences of these interactions, 
Rob Martienssen and his colleagues at 
CSHL found that different transposons 
respond to different types of epigenetic 
regulation and identified two distinct 
mechanisms of transposon silencing that 
likely interact in a common pathway.
The challenge of teasing out the 
individual contributions of these highly 
complex, overlapping regulatory 
pathways is complicated by the fact that 
few model organisms suit the task. Fission 
yeast, the organism of choice for many 
fundamental cell biology investigations, 
seems to lack DNA methylation, while 
mice can’t live without it, ruling them out 
as viable subjects for experiments that 
disturb this form of DNA modification. 
The Arabidopsis thaliana plant, on the 
other hand, not only can survive such 
disturbances but can also produce 
offspring ripe for studying epigenetic 
inheritance patterns. Plus, this plant has 
already helped researchers identify many 
genes involved in epigenetic regulation.
To study the molecular basis of 
epigenetic inheritance and the 
interaction of the various regulatory 
networks—DNA methylation, histone 
modification, and RNA interference—
Martienssen et al. used several 
Arabidopsis strains with mutations 
known to affect these processes as well 
as the epigenetic inheritance of active 
transposons. DNA methylation chemically 
modifies DNA; histone proteins are 
modified by other molecules and alter 
chromatin structure (the complex of 
DNA and proteins that packages DNA 
in cells); and RNA interference (RNAi) 
blocks DNA transcription. Focusing on 
a representative group of transposons, 
Martienssen et al. crossed mutants in 
DNA methylation, histone modification, 
and chromatin remodeling with 
nonmutant plants and characterized the 
impacts on each transposon.
Using transposon expression 
(transposons must be expressed to jump 
around) in the offspring to determine 
whether transposable elements were 
silent, transiently activated, or heritably 
activated, the researchers found that 
when each of the transposons were 
subjected to the same mutations, they 
did not all respond in the same way. 
While some mutations affected all of the 
elements, other mutations affected only a 
subset. The quality of the responses also 
varied; some mutations caused changes 
that were transient, that is, lost in the next 
generation, while others were inherited. 
They also found that RNAi, 
which silences transposable 
elements in fruitflies (Drosophila) 
and worms (Caenorhabditis 
elegans), influences epigenetic 
inheritance. Small interfering 
RNA (siRNA), however, somehow 
interacts with other pathways, 
such as DNA methylation and 
chromatin remodeling, to do so.
Martienssen et al. say these 
results indicate that transposons 
differ in their pattern of 
regulation and tend to respond 
to different types of epigenetic 
regulation, suggesting there 
are distinct mechanisms of 
transposon silencing but 
that the mechanisms or 
pathways probably interact. 
Given the potentially damaging effects 
of transposition and its seemingly 
ubiquitous presence in living things, 
it’s reasonable to wonder whether 
transposable elements evolved 
as a flexible response to special 
circumstances, like environmental stress, 
a possibility proposed by McClintock. 
The epigenetic mechanisms that control 
these elements are vital in regulating 
the structure and organization of the 
genome and in establishing the right 
balance between genetic variation 
and fidelity, the molecular foundation 
of evolution. It seems only fitting that 
biologists at Cold Spring Harbor would 
continue to plumb the implications of 
McClintock’s work—and that their model 
system of choice would be a plant.
Lippman Z, May B, Yordan C, Singer T, 
Martienssen R (2003) Distinct mechanisms 
determine transposon inheritance and 
methylation via small interfering RNA 
and histone modification. DOI: 10.1371/
journal/pbio.0000067
Distinct Mechanisms Control Transposon Inheritance through Overlapping Pathways
Jumping genes discovered in maize through their effect on 
kernel pigmentationVolume 1  |  Issue 3  |  Page 309 PLoS Biology  |  http://biology.plosjournals.org
When a pathogen slips into your body, its chances of escaping detection are slim, 
thanks to the highly specialized surveillance team of the immune system. If a virus, for 
example, succeeds in duping a cell’s molecular machinery into manufacturing new 
copies of itself, the cell responds by breaking a few of the pathogen’s proteins into 
fragments and displaying some of these peptides (or antigens) on its surface. There, 
held in the grips of cell surface proteins called MHC (major histocompatibility complex) 
proteins, antigens can be recognized as foreign to circulating T lymphocytes. The body 
produces billions of these white blood cells every day, each outfitted with specialized 
T cell receptors and MHC proteins outfitted to recognize a unique antigen. This 
exquisitely specific recognition of antigens—displayed on the cell surface by an MHC 
protein—is the critical step leading 
to the proliferation, activation, and 
differentiation of T cell clones specially 
equipped to destroy that pathogen.
The detection of  “antigen-
specific’’  T cell populations can 
provide insight into the physiology 
of the immune system and how it 
responds appropriately to disease 
or inappropriately to host proteins 
in autoimmune disorders. Scientists 
have linked different T cell responses 
to specific antigens associated 
with microbes, autoimmune 
diseases, allergens, and cancer cells. 
Understanding how the immune 
system responds to such pathogens—
and how it functions in the absence of disease—depends on being able to detect and 
evaluate these responses. But since different populations of T cells can interact with 
diverse antigens simultaneously, identifying and characterizing these populations has 
presented a huge challenge. Yoav Soen, Daniel Chen, Daniel Kraft, Mark Davis, and Pat 
Brown have developed a high-volume screen that not only sorts and identifies multiple 
antigen-specific T cell populations from a diverse sample, but also determines which 
populations are active, even when the response is weak.
Faced with the challenge of identifying huge numbers of antigen-specific cells with 
a wide range of peptide-MHC complexes, Soen et al. turned to the high-throughput 
technology of microarrays. But instead of using bits of DNA as probes to latch on to 
active genes in cell samples, the researchers used arrays of peptide-MHC complexes 
to capture antigen-specific T cells. They printed tiny spots of different peptide-MHC 
complexes on glass slides and then layered populations of T cells onto the slides, 
where the T cells could interact with each of the printed peptide-MHC complexes. 
The rare cells that recognize each specific peptide-MHC complex are captured at the 
corresponding spot on the microarray, where they can be counted and assayed. With 
this new microarray, immunology researchers—traditionally restricted to identifying 
and quantifying only a few lymphocyte populations at a time—can now characterize 
hundreds or thousands at a time.
To test the reliability of the microarray, the researchers labeled different populations 
of T lymphocytes based on their antigen-binding specificities and found that the array 
accurately detected each population. The ability to sort out and assay rare cells that 
recognize specific antigens will be useful for a wide range of applications, including 
vaccine development. The researchers also demonstrated the array’s sensitivity by 
successfully detecting a weak, specific immune response in cells extracted from 
vaccinated mice. Such an application would be a valuable tool for monitoring the global 
population of T cells in a living organism—including human patients—in response to 
vaccination, infection, autoimmunity, and other diseases.
Soen Y, Chen DS, Kraft DL, Davis MM, Brown PO (2003) Detection and characterization 
of cellular immune responses using peptide-MHC microarrays. DOI: 10.1371/journal/
pbio.0000065
New Microarray Detects Antigen-Specific T Cells 
and Immune Responses
Calcium flux in activated lymphocytes
Scientific progress in biology typically 
relies on incremental advances that 
explain a small piece of an impossibly 
complex puzzle. But sometimes, 
understanding that one piece is 
enough. Scientists have long known 
that a rare cancer syndrome, called von 
Hippel–Lindau (VHL), had a hereditary 
component. First seen clustering in 
families over a century ago, the disease 
is characterized by vascular tumors, 
including retinal and central nervous 
system “hemangioblastomas’’ and clear-
cell carcinomas of the kidney and adrenal 
glands. Just ten years ago, scientists 
identified the tumor suppressor gene, 
called VHL, that causes the disease and 
later discovered how loss of VHL leads to 
cancer.
It had appeared this pathway was 
uncommonly simple. VHL regulates HIF 
(hypoxia-inducible factor), a transcription 
factor that controls cellular responses 
to below-normal oxygen levels in the 
blood or tissue, a condition known as 
hypoxia. In the presence of oxygen, the 
VHL gene product pVHL forms a complex 
with other proteins and targets HIF for 
degradation. In response to hypoxia, 
HIF activity increases and induces the 
expression of a number of proteins that 
help cells adapt to low levels of oxygen. 
If VHL function is lost, it cannot target 
HIF, leading to a stable accumulation of 
HIF and a corresponding overproduction 
of the hypoxia-induced proteins. When 
aberrantly produced, these proteins 
contribute to tumor formation and 
growth through angiogenesis (the 
mass of blood vessels characteristic of 
hemangioblastomas) and unregulated 
cell growth. But subsequent studies 
suggested that VHL might have other 
targets, raising the possibility that HIF 
might not be the sole, or even primary, 
mediator of tumor formation in cells 
lacking pVHL. Now William Kaelin and 
colleagues report that inhibiting HIF is 
not only necessary to support pVHL’s 
function as a tumor suppressor, but that it 
is also enough.
The researchers set out to determine 
whether the inhibition of HIF was 
specifically responsible for pVHL’s 
reported tumor suppressive effects. 
When pVHL is reintroduced into human 
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renal carcinoma cells lacking pVHL and 
overexpressing HIF2α, HIF2α levels go 
down, hypoxia-inducible gene expression 
goes down, and tumorigenesis is 
suppressed. Kaelin et al. found that 
introducing HIF2α variants lacking 
specific pVHL-binding sites into such 
cells was sufficient to negate pVHL’s 
tumor suppressor activity, implying 
that inhibition of HIF is necessary for 
pVHL to suppress tumor growth. To see 
whether simply removing HIF2α would 
mimic the tumor suppressor activity of 
pVHL, the researchers introduced “short 
hairpin’’ RNAs (shRNAs) to “silence’’ HIF2α 
protein production. The shRNA-treated 
cells (which lacked functional VHL genes) 
showed decreased levels of HIF2α activity 
and were grossly impaired with respect 
to facilitating tumor formation in mice. 
These results suggest that, while pVHL 
may have multiple functions, inhibition of 
HIF can account for its ability to suppress 
tumor growth, at least in the context of 
renal carcinoma.
Tumor suppressor genes are defined 
by what happens in their absence—while 
their normal function is not always 
apparent, it is clear that their loss of 
function results in cancer susceptibility—
and by the fact that they usually require 
loss of both versions, or alleles, for 
damage to occur. While patients with 
VHL inherit one mutated copy and later 
acquire a mutation in the second copy, 
patients with similar but nonhereditary 
vascular cancers have also lost both 
VHL alleles. Knowing HIF’s role as the 
fulcrum between health and disease, 
scientists can now concentrate on just 
that one piece of the puzzle—HIF and its 
target genes—to develop customized 
preventive and therapeutic treatments 
not only for VHL patients but for those 
living with nonhereditary tumors, such 
as kidney cancers, that frequently result 
from pVHL inactivation.
Kondo K, Kim W, Lechpammer M, Kaelin 
WG Jr (2003) Inhibition of HIF2a is 
sufficient to suppress pVHL-defective 
tumor growth. DOI: 10.1371/journal/
pbio.0000083
Tumor suppression by HIF2α shRNA